Trastuzumab in adjuvant therapy for early-stage breast cancer

Steven J. Tucker; Matt Stenger; Edith A. Perez

doi:10.1016/s1548-5315(11)70611-8

Trastuzumab in adjuvant therapy for early-stage breast cancer

Steven J. Tucker, Matt Stenger, Edith A. Perez

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Review article › peer-review

Abstract

It was the topic that set ASCO on its ear: current trials now indicate that adding trastuzumab prolongs disease-free survival. The data are so strong, they warrant a change in the standard of care from adjuvant anthracycline therapy, with or without taxanes, to adjuvant treatment with trastuzumab for eligible patients with HER2+ resected breast cancer.

Original language	English (US)
Pages (from-to)	388-390+395
Journal	Community Oncology
Volume	2
Issue number	5
DOIs	https://doi.org/10.1016/s1548-5315(11)70611-8
State	Published - 2005

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/s1548-5315(11)70611-8

Cite this

@article{0443e6c5fdce43639d8ac61911e7959a,

title = "Trastuzumab in adjuvant therapy for early-stage breast cancer",

abstract = "It was the topic that set ASCO on its ear: current trials now indicate that adding trastuzumab prolongs disease-free survival. The data are so strong, they warrant a change in the standard of care from adjuvant anthracycline therapy, with or without taxanes, to adjuvant treatment with trastuzumab for eligible patients with HER2+ resected breast cancer.",

author = "Tucker, {Steven J.} and Matt Stenger and Perez, {Edith A.}",

year = "2005",

doi = "10.1016/s1548-5315(11)70611-8",

language = "English (US)",

volume = "2",

pages = "388--390+395",

journal = "Community Oncology",

issn = "1548-5315",

publisher = "BioLink Communications",

number = "5",

}

TY - JOUR

T1 - Trastuzumab in adjuvant therapy for early-stage breast cancer

AU - Tucker, Steven J.

AU - Stenger, Matt

AU - Perez, Edith A.

PY - 2005

Y1 - 2005

N2 - It was the topic that set ASCO on its ear: current trials now indicate that adding trastuzumab prolongs disease-free survival. The data are so strong, they warrant a change in the standard of care from adjuvant anthracycline therapy, with or without taxanes, to adjuvant treatment with trastuzumab for eligible patients with HER2+ resected breast cancer.

AB - It was the topic that set ASCO on its ear: current trials now indicate that adding trastuzumab prolongs disease-free survival. The data are so strong, they warrant a change in the standard of care from adjuvant anthracycline therapy, with or without taxanes, to adjuvant treatment with trastuzumab for eligible patients with HER2+ resected breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=25444445564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444445564&partnerID=8YFLogxK

U2 - 10.1016/s1548-5315(11)70611-8

DO - 10.1016/s1548-5315(11)70611-8

M3 - Review article

AN - SCOPUS:25444445564

SN - 1548-5315

VL - 2

SP - 388-390+395

JO - Community Oncology

JF - Community Oncology

IS - 5

ER -

Trastuzumab in adjuvant therapy for early-stage breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this